Home › Companies › BIOMARIN PHARMACEUTICAL INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and BIOMARIN PHARMACEUTICAL INC.’s Form 8-K, filed May 24, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 21, 2024: 13 items on BIOMARIN PHARMACEUTICAL INC.’s Form 8-K, filed May 24, 2024: 11 elected · 2 approved.
No notable dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore BIOMARIN PHARMACEUTICAL INC. in the interactive database Compare manager voting policies
These tallies are BIOMARIN PHARMACEUTICAL INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 24, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Elizabeth McKee Anderson | 143,725,729 | -- | -- | 9,003,309 | 10,260,612 | 94% | Elected | — |
| Elect Director: Barbara W. Bodem | 152,126,450 | -- | -- | 602,588 | 10,260,612 | 99.6% | Elected | — |
| Elect Director: Athena Countouriotis, M.D. | 152,107,502 | -- | -- | 621,536 | 10,260,612 | 99.6% | Elected | — |
| Elect Director: Willard Dere, M.D. | 147,153,181 | -- | -- | 5,575,857 | 10,260,612 | 96% | Elected | — |
| Elect Director: Mark J. Enyedy | 152,125,947 | -- | -- | 603,091 | 10,260,612 | 99.6% | Elected | — |
| Elect Director: Alexander Hardy | 151,780,693 | -- | -- | 948,345 | 10,260,612 | 99.4% | Elected | — |
| Elect Director: Elaine J. Heron, Ph.D. | 144,192,766 | -- | -- | 8,536,272 | 10,260,612 | 94% | Elected | — |
| Elect Director: Maykin Ho, Ph.D. | 143,813,807 | -- | -- | 8,915,231 | 10,260,612 | 94% | Elected | — |
| Elect Director: Robert J. Hombach | 149,094,947 | -- | -- | 3,634,091 | 10,260,612 | 98% | Elected | — |
| Elect Director: Richard A. Meier | 146,622,137 | -- | -- | 6,106,901 | 10,260,612 | 96% | Elected | — |
| Elect Director: David E.I. Pyott, M.D. (Hon.) | 146,332,496 | -- | -- | 6,396,542 | 10,260,612 | 96% | Elected | — |
| 2. Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year ending December 31, 2024, as set forth in the Proxy | 156,548,552 | 6,404,458 | 36,640 | -- | -- | 96% | Approved | — |
| 3. Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement | 141,887,490 | 10,757,670 | 83,878 | -- | 10,260,612 | 93% | Approved | — |
Source: BIOMARIN PHARMACEUTICAL INC., Form 8-K, filed with the SEC on May 24, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
577 asset managers disclosed a vote on at least one BIOMARIN PHARMACEUTICAL INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
99.4% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Alexander Hardy
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Alexander Hardy”): 151,780,693 for, 948,345 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 99.4% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 129 asset managers below reported 80,551,574 for, 640 withheld, 14,575 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,558 | 0 | 0 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 620,525 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 129 asset managers. All 129 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Athena Countouriotis
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Athena Countouriotis, M.D.”): 152,107,502 for, 621,536 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 129 asset managers below reported 80,553,944 for, 640 withheld, 12,205 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,558 | 0 | 0 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 620,525 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 129 asset managers. All 129 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTORS: Barbara W. Bodem
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Barbara W. Bodem”): 152,126,450 for, 602,588 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 129 asset managers below reported 80,553,944 for, 640 withheld, 12,205 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,558 | 0 | 0 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 620,525 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 129 asset managers. All 129 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: David E.I. Pyott
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: David E.I. Pyott, M.D. (Hon.)”): 146,332,496 for, 6,396,542 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 129 asset managers below reported 80,526,418 for, 21,053 withheld, 19,318 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,327 | 0 | 0 | 231 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 620,525 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 129 asset managers. All 129 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Elaine J. Heron
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Elaine J. Heron, Ph.D.”): 144,192,766 for, 8,536,272 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 129 asset managers below reported 79,283,985 for, 1,245,985 withheld, 36,819 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,184 | 0 | 0 | 374 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 0 | 0 | 0 | 873,001 | Withhold |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 620,525 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 342,551 | Withhold |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 129 asset managers. All 129 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Elizabeth M. Anderson
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Elizabeth McKee Anderson”): 143,725,729 for, 9,003,309 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 129 asset managers below reported 80,526,418 for, 21,053 withheld, 19,318 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,327 | 0 | 0 | 231 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 620,525 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 129 asset managers. All 129 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Mark J. Enyedy
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Mark J. Enyedy”): 152,125,947 for, 603,091 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 129 asset managers below reported 80,553,944 for, 640 withheld, 12,205 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,558 | 0 | 0 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 620,525 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 129 asset managers. All 129 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Maykin Ho
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Maykin Ho, Ph.D.”): 143,813,807 for, 8,915,231 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 129 asset managers below reported 77,410,424 for, 2,861,210 withheld, 295,155 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,883,747 | 0 | 0 | 89,167 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,448 | 0 | 0 | 110 | For |
| Charles Schwab | 0 | 0 | 0 | 1,328,936 | Withhold |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 0 | 0 | 0 | 873,001 | Withhold |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 620,525 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 129 asset managers. All 129 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Richard A. Meier
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Richard A. Meier”): 146,622,137 for, 6,106,901 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 129 asset managers below reported 80,169,251 for, 385,333 withheld, 12,205 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,412 | 0 | 0 | 146 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 620,525 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 342,551 | Withhold |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 129 asset managers. All 129 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Robert J. Hombach
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Robert J. Hombach”): 149,094,947 for, 3,634,091 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 129 asset managers below reported 80,546,081 for, 1,390 withheld, 19,318 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,448 | 0 | 0 | 110 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 620,525 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 129 asset managers. All 129 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Willard Dere
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Willard Dere, M.D.”): 147,153,181 for, 5,575,857 withheld, per its Form 8-K filed May 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if soo…”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 129 asset managers below reported 79,661,135 for, 893,414 withheld, 12,240 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,327 | 0 | 0 | 231 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 0 | 0 | 0 | 873,001 | Withhold |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 620,525 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 342,551 | 0 | 0 | 0 | For |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 129 asset managers. All 129 are in the interactive database (link above).
Combines 20 wordings of this item as funds reported it.
93% Approved · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“3. Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement, received the follo”): 141,887,490 for, 10,757,670 against — passed, per its Form 8-K filed May 24, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, BioMarin's stockholders approved, on an advisory basis, the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,558 | 0 | 0 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,180,169 | 9,524 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 342,551 | 0 | 0 | Against |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 183,501 | 0 | 0 | 0 | For |
Fund voting reports, all 130 managers: 79,415,775 for, 593,129 against, 1,973 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PRIMECAP MANAGEMENT CO/CA/ | 17,933,372 | 0 | 0 | 0 | For |
| Dodge & Cox | 13,181,239 | 0 | 0 | 0 | For |
| BlackRock | 6,853,356 | 387 | 0 | 0 | For |
| Capital Research Global Investors | 6,517,745 | 0 | 0 | 0 | For |
| VIKING GLOBAL INVESTORS LP | 6,416,288 | 0 | 0 | 0 | For |
| State Street | 6,069,369 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,985,409 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 2,233,162 | 0 | 0 | 0 | For |
| JPMorgan | 1,827,547 | 0 | 0 | 0 | For |
| Newton Investment Management North America, LLC | 1,650,301 | 0 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 1,587,644 | 0 | 0 | 0 | For |
| Palo Alto Investors LP | 1,500,749 | 0 | 0 | 0 | For |
| Citadel | 1,464,076 | 0 | 0 | 0 | For |
| Charles Schwab | 1,463,021 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 1,224,356 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,181,459 | 0 | 0 | 0 | For |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 0 | 1,113,212 | 0 | 0 | Against |
| ORBIMED ADVISORS LLC | 1,083,500 | 0 | 0 | 0 | For |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | 1,052,717 | 0 | 0 | 0 | For |
| Northern Trust | 1,019,583 | 9,005 | 0 | 0 | For |
| Legal & General Investment Management Ltd | 0 | 885,390 | 0 | 0 | Against |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| DnB Asset Management AS | 850,667 | 0 | 0 | 0 | For |
| Nuveen | 827,207 | 0 | 0 | 0 | For |
| Manning & Napier | 0 | 816,140 | 0 | 0 | Against |
Institutional-manager reports, all 475 managers: 100,312,412 for, 7,558,115 against, 95,532 abstained, 634 not voted, 1 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
96% Approved · of votes cast
Description as filed by funds: TO RATIFY THE SELECTION OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year ending Decem”): 156,548,552 for, 6,404,458 against — passed, per its Form 8-K filed May 24, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, BioMarin's stockholders ratified the selection of KPMG LLP as BioMarin's independent registered public accounting firm to serve for the year ending December 31, 2024.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 135 asset managers below reported 80,193,262 for, 443,871 against, 1,992 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 30,972,914 | 0 | 0 | 0 | For |
| Dodge & Cox | 10,543,625 | 0 | 0 | 0 | For |
| BlackRock | 5,995,495 | 0 | 0 | 0 | For |
| AMCAP FUND | 4,909,896 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,611,116 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 3,202,466 | 0 | 0 | 0 | For |
| Fidelity | 3,174,229 | 0 | 0 | 0 | For |
| State Street | 2,447,414 | 144 | 0 | 0 | For |
| Charles Schwab | 1,328,936 | 0 | 0 | 0 | For |
| Capital Group | 1,308,486 | 0 | 0 | 0 | For |
| BNY Mellon | 1,189,693 | 0 | 0 | 0 | For |
| CARILLON SERIES TRUST | 1,173,840 | 0 | 0 | 0 | For |
| Parnassus | 873,001 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 846,543 | 0 | 0 | 0 | For |
| T. Rowe Price | 835,656 | 0 | 0 | 0 | For |
| TIAA | 760,907 | 0 | 0 | 0 | For |
| American Century | 678,313 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 620,525 | 0 | 0 | 0 | For |
| First Trust | 481,892 | 0 | 0 | 0 | For |
| Dimensional | 469,077 | 0 | 0 | 0 | For |
| JPMorgan | 459,194 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 342,551 | 0 | 0 | Against |
| Goldman Sachs | 303,293 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 294,486 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 259,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 135 asset managers. All 135 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 189,776,577 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 16.32% |
| 2 | Dodge & Cox | 5.56% |
| 3 | BlackRock | 3.16% |
| 4 | AMCAP FUND | 2.59% |
| 5 | PRIMECAP Odyssey Funds | 1.90% |
| 6 | Columbia Threadneedle | 1.69% |
| 7 | Fidelity | 1.67% |
| 8 | State Street | 1.29% |
| 9 | Charles Schwab | 0.70% |
| 10 | Capital Group | 0.69% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | PRIMECAP MANAGEMENT CO/CA/ | 9.45% |
| 2 | Dodge & Cox | 6.95% |
| 3 | BlackRock | 3.61% |
| 4 | Capital Research Global Investors | 3.43% |
| 5 | VIKING GLOBAL INVESTORS LP | 3.38% |
| 6 | State Street | 3.20% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1.57% |
| 8 | Avoro Capital Advisors LLC | 1.18% |
| 9 | JPMorgan | 0.96% |
| 10 | Newton Investment Management North America, LLC | 0.87% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Vanguard Group | 18,582,585 | 9.79% | Form 13F, quarter ended March 31, 2024 |
| PRIMECAP Management Company | 18,414,374 | 9.70% | Proxy statement (DEF 14A), proxy filed April 9, 2024 |
| BlackRock, Inc. | 14,740,836 | 7.77% | Proxy statement (DEF 14A), proxy filed April 9, 2024 |
| Dodge & Cox | 13,994,063 | 7.37% | Proxy statement (DEF 14A), proxy filed April 9, 2024 |
| S.S. OR | 13,994,063 | 7.37% | Schedule 13G, filed February 13, 2024 |
| Capital Research Global Investors | 10,774,641 | 5.68% | Proxy statement (DEF 14A), proxy filed April 9, 2024 |
| State Street | 6,895,215 | 3.63% | Form 13F, quarter ended March 31, 2024 |
| Norges Bank | 2,884,483 | 1.52% | Form 13F, quarter ended March 31, 2024 |
| Millennium Management | 2,644,979 | 1.39% | Form 13F, quarter ended March 31, 2024 |
| BNY Mellon | 2,637,488 | 1.39% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 189,776,577 shares outstanding, as reported by BIOMARIN PHARMACEUTICAL INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At BIOMARIN PHARMACEUTICAL INC.'s shareholder meeting held May 21, 2024, in the 2023-2024 proxy season, 577 asset managers reported votes on at least one of its 13 ballot items in their SEC Form N-PX filings, covering 6,880 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as… — BIOMARIN PHARMACEUTICAL INC.'s filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BIOMARIN PHARMACEUTICAL INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 24, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BIOMARIN PHARMACEUTICAL INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
BIOMARIN PHARMACEUTICAL INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “BIOMARIN PHARMACEUTICAL (BMRN) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/biomarin-pharmaceutical-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.